Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms

Oncologist

Volumn 18, Issue 4, 2013, Pages 446-453

  Cascales, Almudena ^a   Pastor Quirante, Francisco ^b   Sánchez Vega, Beatriz ^b   Luengo Gil, Ginés ^a,c   Corral, Javier ^a   Ortuño Pacheco, Guzmán ^b   Vicente, Vicente ^a,b,c   De La Peña, Francisco Ayala ^c  

^a HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

Anthracyclines; Genotype; Myocardial fibrosis; NADPH; Secondary myocardial diseases

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; MITOXANTRONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ADULT; ALLELE; ARTICLE; BLEEDING; CARDIOTOXICITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPING TECHNIQUE; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS;

ADULT; ANTHRACYCLINES; AUTOPSY; CASE-CONTROL STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NADPH OXIDASE; NEOPLASMS; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 84877035353     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0239     Document Type: Article

References (42)

1. Gianni L, Herman EH, Lipshultz SE et al. Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 2008;26:3777-3784.
2. Ewer MS, Benjamin RS. Doxorubicin cardiotoxicity: Clinical aspects, recognition, monitoring, treatment and prevention. In: Ewer MS, Yeh E, eds. Cancer andtheHeart.Hamilton,Canada:BCDeckerInc,2006: 9-32.
3. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003; 97:2869-2879.
4. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(suppl 5):v277-v282.
5. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525-533.
6. Hequet O, Le QH, Moullet I et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22: 1864-1871.
7. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clin Cancer Res 2008;14:14-24.
8. Ewer MS, Ali MK, Mackay B et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984;2:112-117.
9. Isner JM, Ferrans VJ, Cohen SR et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. AmJ Cardiol 1983;51:1167-1174.
10. Billingham ME, Mason JW, BristowMRet al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-872.
11. Berry GJ, Jorden M. Pathology of radiation and anthracycline cardiotoxicity. Pediatr Blood Cancer 2005;44:630-637.
12. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: A series of 15 patients. Med Pediatr Oncol 1995;24:352-361.
13. Bernaba BN, Chan JB, Lai CK et al. Pathology of late-onset anthracycline cardiomyopathy. Cardiovasc Pathol 2010;19:308-311.
14. Jensen BV, Skovsgaard T, Nielsen SL. Func-tional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13:699-709.
15. Altena R, Perik PJ, van Veldhuisen DJ et al. Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncol 2009; 10:391-399.
16. Aapro M, Bernard-Marty C, Brain EG et al. Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper. Ann Oncol 2012;22:257-267.
17. Doyle JJ, Neugut AI, Jacobson JS et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23:8597-8605.
18. Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30: 1422-1428.
19. Rossi D, Rasi S, Franceschetti S et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphomatreated withR-CHOP21.Leukemia2009; 23:1118-1126.
20. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin- induced cardiotoxicity. Circulation 2005; 112:3754-3762.
21. Cascales A, Sánchez-Vega B, Navarro N et al. Clinical and genetic determinants of anthracyclineinduced cardiac iron accumulation. Int J Cardiol 2012;154:282-286.
22. Hayashi T, Yamashita C, Matsumoto C et al. Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress. Am J Physiol Heart Circ Physiol 2008; 294:H2197-H2203.
23. Mantovani G, Madeddu C, Cadeddu C et al. Persistence, up to 18 months of follow-up, of epirubicin- induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: Correlation with inflammatory and oxidative stress markers. The Oncologist 2008;13:1296-1305.
24. Zhao Y, McLaughlin D, Robinson E et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Research 2010;70:9287-9297.
25. Johnson SA. Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin Oncol 2006;33(suppl 8):S22-S27.
26. Solç X, Guinó E, Valls J et al. SNPStats: A web tool for the analysis of association studies. Bioinformatics 2006;22:1928-1929.
27. Bland JM, Altman DG. Multiple significance tests: The Bonferroni method. BMJ 1995;310:170.
28. Adamcová M, Potacová A, Popelová O et al. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol Res 2010;59:831-836.
29. Jones RL, Miles DW. Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. Lancet Oncol 2005;6:67.
30. Butany J, Ahn E, Luk A. Drug-related cardiac pathology. J Clin Pathol 2009;62:1074-1084.
31. Li L, Takemura G, Li Y et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin- induced cardiomyopathy. Circulation 2006; 113:535-543.
32. Gilleron M, Marechal X, Montaigne D et al. NADPH oxidases participate to doxorubicin-inducedcardiacmyocyteapoptosis. BiochemBiophys Res Commun 2009;388:727-731.
33. White SK, Sado DM, Flett AS et al. Characterising the myocardial interstitial space: The clinical relevance of non-invasive imaging. Heart 2012;98: 773-779.
34. Marty M, Espié M, Llombart A et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 2006;17:614-622.
35. Barrett-Lee PJ, Dixon JM, Farrell C et al. Expert opinionontheuseof anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009;20:816-827.
36. Minotti G, Menna P, Salvatorelli E et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
37. Murdoch CE, Zhang M, Cave AC et al. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006;71:208-215.
38. Nabeebaccus A, Zhang M, Shah AM. NADPH oxidases and cardiac remodelling. Heart Fail Rev 2011;16:5-12.
39. Maejima Y, Kuroda J, Matsushima S et al. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 2011;50:408-416.
40. Lopes LR, Dagher MC, GutierrezAet al. Phosphorylated p40PHOX as a negative regulator of NADPH oxidase. Biochemistry 2004;43:3723-3730.
41. Guzik TJ, West NE, Black E et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102:1744-1747.
42. Schirmer M, Hoffmann M, Kaya E et al. Genetic polymorphisms of NAD(P)H oxidase: Variation in subunit expression and enzyme activity. Pharmacogenomics J 2008;8:297-304.